SynthesisWorld journal of gastroenterology2015
Increased risk of second malignancy in pancreatic intraductal papillary mucinous tumors: Review of the literature.
Synthesis in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- A meta-analysis: incidental intraductal papillary mucinous neoplasm and extra-pancreatic malignancy.Langenbeck's archives of surgery · 2022Pooled it
- Incidental Finding of Gastric Lesions During Pancreatobiliary Endoscopic Ultrasonography.Digestive diseases and sciences · 2026Article
- Use of an Algo-Based Decision-Making Tool to Compare Real-Life Clinical Practice in a Single Tertiary Center with the Kyoto IPMN Surveillance Recommendations.Journal of clinical medicine · 2026Article
- Esophagogastroduodenal Findings in Patients with Intraductal Papillary Mucinous Neoplasms.Diagnostics (Basel, Switzerland) · 2023Article
- Synchronous manifestation of colorectal cancer and intraductal papillary mucinous neoplasms.World journal of clinical cases · 2023Review
- New Diagnostic Modality Combining Mass Spectrometry and Machine Learning for the Discrimination of Malignant Intraductal Papillary Mucinous Neoplasms.Annals of surgical oncology · 2023Article
- Value of 3-T MR imaging in intraductal papillary mucinous neoplasm with a concomitant invasive carcinoma.European radiology · 2022Article
- Increased prevalence of colorectal neoplasia in patients with intraductal papillary mucinous neoplasms.Therapeutic advances in gastroenterology · 2022Article
- Cystic Neoplasms of the Pancreas: Differential Diagnosis and Radiology Correlation.Frontiers in oncology · 2022Review
- Increased Risk of Second Primary Cancers Following Diagnosis of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Population-Based Study.Frontiers in oncology · 2019Article
- Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives.Current treatment options in gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo analyze the available evidence about the risk of extrapancreatic malignancies and pancreatic ductal adenocarcinoma associated to pancreatic intraductal papillary mucinous tumors (IPMNs).
methodsA systematic search of literature was undertaken using MEDLINE, EMBASE, Cochrane and Web-of-Science libraries. No limitations for year of publication were considered; preference was given to English papers. All references in selected articles were further screened for additional publications. Both clinical series and Literature reviews were selected. For all eligible studies, a standard data extraction form was filled in and the following data were extracted: study design, number of patients, prevalence of pancreatic cancer and extrapancreatic malignancies in IPMN patients and control groups, if available.
resultsA total of 805 abstracts were selected and read; 25 articles were considered pertinent and 17 were chosen for the present systematic review. Eleven monocentric series, 1 multicentric series, 1 case-control study, 1 population-based study and 3 case report were included. A total of 2881 patients were globally analyzed as study group, and the incidence of pancreatic cancer and/or extrapancreatic malignancies ranged from 5% to 52%, with a mean of 28.71%. When a control group was analyzed (6 papers), the same incidence was as low as 9.4%.
conclusionThe available Literature is unanimous in claiming IPMNs to be strongly associated with pancreatic and extrapancreatic malignancies. The consequences in IPMNs management are herein discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.